Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.71 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | ACE | P12821 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.71 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780797 | 0.95 | AGTR1 (0.64) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL13382771 | 0.91 | PPARG (0.75) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL9565910 | 0.90 | PPARG (0.74) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL1249924 | 0.89 | PPARG (0.78) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL16456669 | 0.89 | PPARG (0.68) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL16456732 | 0.87 | PPARG (0.70) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL8268211 | 0.86 | PPARG (0.80) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL809909 | 0.85 | PPARG (0.78) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL12664495 | 0.85 | PPARG (0.77) | PPARGAGTR1AGTR2KDM4EABCC3 | |
| SCHEMBL1249891 | 0.84 | PPARG (0.76) | PPARGAGTR1AGTR2KDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885714-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2014-01-15 | — | — | EP | claimed |
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | LEK PHARMACEUTICALS, D.D. (SI) | 2009-07-09 | — | — | US | claimed |
| EP-1885714-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK Pharmaceuticals D.D. (SI) | 2008-02-13 | — | — | EP | claimed |
| WO-2006125592-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS D.D. (SI) | 2006-11-30 | — | — | WO | claimed |
| EP-1885714-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2014-01-15 | — | — | EP | disclosed |
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | LEK PHARMACEUTICALS, D.D. (SI) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | AGTR1, AGTR2, REN | PPARG 2150/4885AGTR1 1/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.